Wuhan Union Hospital, China: Carcinoma trials

The registry lists 10 Carcinoma studies with Wuhan Union Hospital, China as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 2 7Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Application of PET Imaging Targeting Nectin-4 in Malignant TumorsNot yet recruitingNCT06994078Not applicable
• AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06537011Phase 2
• HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06244225Phase 2
• Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCCNot yet recruitingNCT05993858Phase 2
• Disitamab Vedotin Combined With Radiotherapy for Bladder PreservationNot yet recruitingNCT05912205Phase 2
• Molecular Study and Precision Medicine for Colorectal CancerNot yet recruitingNCT05883683
• Cadonilimab (AK104) in the Treatment of Nasopharyngeal CarcinomaRecruitingNCT05790200Phase 2
• Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular CarcinomaStatus unknownNCT05617430Phase 2
• Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCCActive, not recruitingNCT05459415Not applicable
• The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label StudyStatus unknownNCT04909866Phase 2/3